126 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
Compared to Estimates, M&T Bank Corporation (MTB) Q4 Earnings: A Look at Key Metrics https://www.zacks.com/stock/news/2212081/compared-to-estimates-m-t-bank-corporation-mtb-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2212081 Jan 18, 2024 - While the top- and bottom-line numbers for M&T Bank Corporation (MTB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Unveiling AT&T (T) Q4 Outlook: Wall Street Estimates for Key Metrics https://www.zacks.com/stock/news/2213002/unveiling-at-t-t-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2213002 Jan 19, 2024 - Get a deeper insight into the potential performance of AT&T (T) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Unlocking Q4 Potential of T-Mobile (TMUS): Exploring Wall Street Estimates for Key Metrics https://www.zacks.com/stock/news/2214498/unlocking-q4-potential-of-t-mobile-tmus-exploring-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2214498 Jan 23, 2024 - Beyond analysts' top -and-bottom-line estimates for T-Mobile (TMUS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Compared to Estimates, T-Mobile (TMUS) Q4 Earnings: A Look at Key Metrics https://www.zacks.com/stock/news/2216184/compared-to-estimates-t-mobile-tmus-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2216184 Jan 25, 2024 - Although the revenue and EPS for T-Mobile (TMUS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
S&T Bancorp (STBA) Reports Q4 Earnings: What Key Metrics Have to Say https://www.zacks.com/stock/news/2215952/s-t-bancorp-stba-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2215952 Jan 25, 2024 - While the top- and bottom-line numbers for S&T Bancorp (STBA) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Top Research Reports for Abbott, T-Mobile & Booking https://www.zacks.com/commentary/2219543/top-research-reports-for-abbott-t-mobile-booking?cid=CS-ZC-FT-research_daily-2219543 Feb 01, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories (ABT), T-Mobile US, Inc. (TMUS) Booking Holdings Inc. (BKNG).
T. Rowe Price (TROW) to Post Q4 Earnings: What's in the Cards? https://www.zacks.com/stock/news/2219670/t-rowe-price-trow-to-post-q4-earnings-what-s-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-2219670 Feb 01, 2024 - T. Rowe Price (TROW) is expected to have witnessed an improvement in AUM in the fourth quarter of 2023 due to favourable equity market performance partially offset by net outflows.
T. Rowe Price (TROW) Expected to Beat Earnings Estimates: Should You Buy? https://www.zacks.com/stock/news/2219608/t-rowe-price-trow-expected-to-beat-earnings-estimates-should-you-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2219608 Feb 01, 2024 - T. Rowe (TROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fda-s-odac?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221922 Feb 06, 2024 - Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
T. Rowe Price (TROW) Q4 Earnings Beat Estimates, AUM Rises Y/Y https://www.zacks.com/stock/news/2223559/t-rowe-price-trow-q4-earnings-beat-estimates-aum-rises-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2223559 Feb 08, 2024 - T. Rowe Price's (TROW) Q4 earnings beat estimates on increased net revenues, an improvement in AUM and a decline in expenses. A rise in cash and cash equivalents will help it continue investing.

Pages: 1...678910111213

<<<Page 11>